John W. Smither's most recent trade in NewAmsterdam Pharma Company NV was a trade of 32,500 Option (right to buy) done . Disclosure was reported to the exchange on Jan. 6, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Compan... | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 32,500 | 32,500 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Compan... | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 6,960 | 6,960 | - | - | Ordinary Shares | |
| Genelux Corp | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 50,469 | 50,469 | - | - | Stock Option Right to Buy) | |
| Genelux Corp | Smither John W. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 50,469 | 50,469 | - | - | Stock Option Right to Buy) | |
| Genelux Corp | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 39,541 | 52,711 | - | 0 | Common Stock | |
| Genelux Corp | John W. Smither | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 6,250 | 13,170 | - | - | Common Stock | |
| Genelux Corp | John W. Smither | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 6,250 | 6,250 | - | - | Common Stock Warrant (Right to Buy) | |
| Arcutis Biotherapeutics Inc | John Smither W. | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 25,718 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Smither W. John | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 8,572 | 11,365 (0%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | John Smither W. | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 8,379 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Smither W. John | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 2,793 | 2,793 (0%) | 0% | - | Common Stock | |
| NewAmsterdam Pharma Compan... | W. Smither John | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 10,000 | 10,000 | - | - | Option (right to buy) | |
| Applied Molecular Transpor... | W. Smither John | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 60,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | John W. Smither | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Smither John W. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 36,875 | 36,875 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2021 | 24,142 | 24,142 | - | - | Common Stock | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2021 | 24,142 | 24,142 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2021 | 3,556 | 3,556 | - | - | Earn-out Right | |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.90 per share. | 10 Mar 2021 | 1,250 | 86,715 (0%) | 0% | 32.9 | 41,125 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 500 | 44,982 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.90 per share. | 10 Mar 2021 | 500 | 46,321 (0%) | 0% | 32.9 | 16,450 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 10 Mar 2021 | 500 | 46,821 (0%) | 0% | 1.7 | 840 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 28,800 | 28,800 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2021 | 12,396 | 97,684 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 03 Mar 2021 | 12,396 | 46,321 (0%) | 0% | 1.7 | 20,833 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 9,500 | 33,925 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 34.20 per share. | 01 Mar 2021 | 773 | 24,425 (0%) | 0% | 34.2 | 26,440 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.64 per share. | 10 Feb 2021 | 2,000 | 87,965 (0%) | 0% | 35.6 | 71,280 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.64 per share. | 10 Feb 2021 | 750 | 25,198 (0%) | 0% | 35.6 | 26,730 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2021 | 750 | 45,482 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 10 Feb 2021 | 750 | 25,948 (0%) | 0% | 1.7 | 1,260 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 01 Feb 2021 | 3,750 | 89,965 (0%) | 0% | 35 | 131,250 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 01 Feb 2021 | 1,250 | 25,198 (0%) | 0% | 35 | 43,750 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 1,250 | 46,232 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 01 Feb 2021 | 1,250 | 26,448 (0%) | 0% | 1.7 | 2,101 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 19 Jan 2021 | 1,250 | 93,715 (0%) | 0% | 30 | 37,500 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 19 Jan 2021 | 500 | 25,698 (0%) | 0% | 1.7 | 840 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 500 | 47,482 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 19 Jan 2021 | 500 | 25,198 (0%) | 0% | 30 | 15,000 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 14 Dec 2020 | 3,750 | 94,965 (0%) | 0% | 30 | 112,500 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2020 | 1,500 | 47,982 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 14 Dec 2020 | 1,500 | 26,698 (0%) | 0% | 1.7 | 2,521 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 14 Dec 2020 | 1,500 | 25,198 (0%) | 0% | 30 | 45,000 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 29 Sep 2020 | 1,250 | 98,715 (0%) | 0% | 30 | 37,500 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 29 Sep 2020 | 500 | 24,375 (0%) | 0% | 1.7 | 840 | Common Stock |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Sep 2020 | 500 | 49,482 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | John W. Smither | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 29 Sep 2020 | 500 | 23,875 (0%) | 0% | 30 | 15,000 | Common Stock |